In a recent development, Tarsus Pharmaceuticals (TARS, Financial) received positive attention from HC Wainwright & Co., as the firm announced a new coverage. Matthew Caufield, an analyst from HC Wainwright & Co., has initiated a "Buy" rating on Tarsus Pharmaceuticals (TARS).
The financial company has set a price target of $72.00 USD for Tarsus Pharmaceuticals (TARS, Financial). This marks a promising outlook for the stock as it moves forward with this strategic guidance from the analyst. It is noteworthy that this is the initial coverage from HC Wainwright & Co. with no prior recorded target price or rating adjustment for Tarsus Pharmaceuticals (TARS).
Investors and market watchers may keep a close eye on Tarsus Pharmaceuticals (TARS, Financial), as the "Buy" rating and the forecasted target price reflect a positive sentiment towards the stock's potential performance in the coming periods.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Tarsus Pharmaceuticals Inc (TARS, Financial) is $70.71 with a high estimate of $85.00 and a low estimate of $51.00. The average target implies an upside of 64.53% from the current price of $42.98. More detailed estimate data can be found on the Tarsus Pharmaceuticals Inc (TARS) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Tarsus Pharmaceuticals Inc's (TARS, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Tarsus Pharmaceuticals Inc (TARS, Financial) in one year is $248.28, suggesting a upside of 477.66% from the current price of $42.98. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Tarsus Pharmaceuticals Inc (TARS) Summary page.
